Thrombocythemia, Essential
Information
- Disease name
- Thrombocythemia, Essential
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05223920 | Active, not recruiting | Phase 2 | Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | December 16, 2021 | August 22, 2024 |
| NCT02912884 | Completed | Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure | September 2016 | October 31, 2020 | |
| NCT00567502 | Completed | Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments | May 31, 2005 | April 30, 2014 | |
| NCT01134120 | Completed | Phase 1 | A Study in Myeloproliferative Disorders | April 2010 | February 22, 2018 |
| NCT06351631 | Recruiting | Phase 3 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | May 23, 2024 | December 4, 2034 |
| NCT04081220 | Recruiting | Phase 2 | Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 | April 9, 2020 | January 2025 |
| NCT00522574 | Terminated | Phase 1 | A Safety Study of XL019 in Adults With Myelofibrosis | August 2007 | |
| NCT01816022 | Unknown status | Myeloproliferative Neoplasms and Bone Structure | March 2012 | March 2015 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D013920